The co-founders of ClinMet, Dr. Kumar Sharma and Ms. Shoba Sharma, and Dr. Emile Loria resigned their positions with ClinMet in October of 2015. The Company is no longer actively conducting business, but retains all intellectual property rights derived from ClinMet’s prior operations.
ClinMet uses metabolomics to provide pharmaceutical companies with clinically relevant and practical insight into drug response and safety for renal and cardiovascular diseases, obesity and diabetes. Our unique combination of skills to achieve exhaustive understanding of a disease along with detailed clinical insights, signature panel of urine-based metabolomic biomarkers, proprietary metabolomics and computational expertise will accelerate the speed and success rate of drug development. ClinMet helps drug developers to efficiently transform promising compounds into safe and effective medicines. Our efficacy and toxicity indices enable pharmaceutical companies to make better clinical trial-related decisions and provide an increased understanding of a drug's mechanism of action.